drugset / Trial / NCT00900783

A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster

NCT00900783

Phase 2 Completed 350 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the safety and efficacy of two doses of FV-100 to valacyclovir in patients with herpes zoster, or shingles. FV-100 has shown to be very potent in cells infected with varicella zoster virus, the virus that causes shingles. The study objectives include: * Compare the safety of FV-100 to valacyclovir * Compare the effect of FV-100, as compared to valacyclovir, on shingles pain * Compare the effect of FV-100, as compared to valacyclovir, on shingles lesions

Timeline

Start
2009-05
Primary completion
2010-11
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject VALNIVUDINE Small molecule 200 mg
Subject VALNIVUDINE Small molecule 400 mg
Comparator Valacyclovir Unknown 1 g

Indications